MG
CKPT

Michael Gelband’s Checkpoint Therapeutics CKPT Stock Holding History

Michael Gelband’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,755
Closed -$49K – 1994
2022
Q1 		$49K Buy
2,755
+182
+7% +$3.91K ﹤0.01% 2066
2021
Q4 		$80K Buy
2,573
+835
+48% +$27.6K ﹤0.01% 1985
2021
Q3 		$57K Sell
1,738
-3,126
-64% -$92.4K ﹤0.01% 1962
2021
Q2 		$143K Buy
4,864
+3,501
+257% +$97K ﹤0.01% 2069
2021
Q1 		$43K Buy
+1,363
New +$45.7K ﹤0.01% 2039
2020
Q2 		– Sell
-1,365
Closed -$21K – 1797
2020
Q1 		$21K Buy
+1,365
New +$24.2K ﹤0.01% 1004
2019
Q2 		– Sell
-3,542
Closed -$101K – 1125
2019
Q1 		$101K Buy
+3,542
New +$113K 0.01% 611

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Michael Gelband's CKPT Position: Q2 2022 in Review

Michael Gelband sold out of Checkpoint Therapeutics (CKPT) in Q2 2022, closing a stake of 2,755 shares — an estimated $49K sold.

Michael Gelband first reported a position in CKPT in Q1 2019 and held it in 7 quarters. The position peaked at $143K in Q2 2021. 62 funds tracked by Wall St. Rank hold CKPT as of Q2 2022.

  • Michael Gelband reported no remaining Checkpoint Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Michael Gelband sold 2,755 Checkpoint Therapeutics shares in Q2 2022, an estimated $49K.
  • Michael Gelband first reported a position in Checkpoint Therapeutics in Q1 2019 and held it in 7 quarters.
  • Michael Gelband's Checkpoint Therapeutics position peaked at $143K in Q2 2021.
  • 62 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.